Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK

Infection and Immunity

Volumn 72, Issue 8, 2004, Pages 4521-4527

  Pinto, Eduardo Fonseca ^c   Pinheiro, Roberta Olmo ^a   Rayol, Alice ^a   Larraga, Vicente ^b   Rossi Bergmann, Bartira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; LACK DNA ANTIGEN; LEISHMANIA ANTIGEN; PLASMID DNA; PROTEIN P 36; PROTOZOAL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNITY; IN VIVO STUDY; LEISHMANIA; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TH1 CELL; TREATMENT OUTCOME; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, PROTOZOAN; DNA, PROTOZOAN; INTERFERON TYPE II; INTERLEUKIN-10; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PARTICLE SIZE; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SOLUBILITY; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME; VACCINATION;

EID: 3342986328     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.8.4521-4527.2004     Document Type: Article

References (39)

1. Bakke, H., K. Lie, I. L. Haugen, G. E. Korsvold, E. A. Høiby, L. M. Næss, J. Holst, I. S. Aaberge, F. Oftung, and B. Haneberg. 2001. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect. Immun. 69:5010-5015.
2. Barnes, A. G. C., C. Barnfield, R. Brew, and L. S. Klavinskis. 2000. Recent developments in mucosal delivery of pDNA vaccines. Curr. Opin. Mol. Ther. 2:87-93.
3. + regulatory T cells in Leishmania infection. Expert Opin. Biol. Ther. 3:875-885.
4. Campbell, M., H. Diao, J. X. Ji, and L. Soong. 2003. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect. Immun. 71:6270-6278.
5. Chen, L. H., J. Wang, A. Zganiacz, and Z. Xing. 2004. Single intranasal mucosal Mycobactetium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72:238-246.
6. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
7. Czerkinsky, C., F. Anjuere, J. R. McGhee, A. George-Chandy, J. Holmgren, M. Kieny, K. Fujiyashi, J. F. Mestecky, V. Pierrefite-Carle, C. Rask, and J. Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:197-222.
8. Dhaliwal, J. S., and F. Y. Liew. 1987. Induction of delayed-type hypersensitivity to Leishmania major and the concomitant acceleration of disease development in progressive murine cutaneous leishmaniasis. Infect. Immun. 55:645-651.
9. Dumonteil, E., R. S. M. Jesus, E. O. Javier, and G. M. M. del Rosario. 2003. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21:2161-2168.
10. Fujihashi, K., T. Koga, F. W. van Ginkel, Y. Hagiwara, and J. R. McGhee. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20:2431-2438.
11. Gonzalez-Aseguinolaza, G., S. Taladriz, A. Marquet, and V. Larraga. 1999. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur. J. Biochem. 259:909-916.
12. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
13. Hamann, A., D. P. Andrew, D. Jablonskiwestrich, B. Hoizmann, and E. C. Butcher. 1994. Role of alpha (4)-integrins in lymphocyte homing to mucosal tissues in-vivo. J. Immunol. 152:3282-3293.
14. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:229-243.
15. Jones, D. E., M. R. Ackermann, U. Wille, C. A. Hunter, and P. Scott. 2002. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70:2151-2158.
16. Julia, V, M. Rassouizadegan, and N. Glaichenhaus. 1996. Resistance to Leishmania major induced by tolerance to a single antigen. Science 274:421-423.
17. + T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major. J. Immunol. 165:5637-5645.
18. Kaiserlian, D., and N. Etchart. 1999. Entry sites for oral vaccines and drugs: a role for M cells, enterocytes and dendritic cells? Semin. Immunol. 11:217-224.
19. Kenney, R. T., D. L. Sacks, J. P. Sypek, L. Vilela, A. A. Gam, and K. Evans-Davis. 1999. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:4481-4488.
20. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6:541-549.
21. Liew, F. Y., C. Hale, and J. G. Howard. 1985. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135:2095-2101.
22. Lira, R., S. Sundar, A. Makharia, R. Kenney, A. Gam, E. Saraiva, and D. Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
23. Makala, L. H. C., Y. Nishikawa, N. Suzuki, and H. Nagasawa. 2004. Immunology-antigen-presenting cells in the gut. J. Biomed. Sci. 11:130-141.
24. Marzochi, K. B. F., M. C. A. Marzochi, A. F. Silva, N. Grativol, R. Duarte, E. M. Conort, and F. Modabber. 1998. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem. Inst. Oswaldo Cruz 93:205-212.
25. McCluskie, M. J., and H. L. Davis. 1998. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:4463-4466.
26. McSorley, S. J., C. Rask, R. Pichot, V. Julia, C. Czerkinsky, and N. Glaichenhaus. 1998. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur. J. Immunol. 28:424-432.
27. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
28. Mendez, A., Y. Belkaid, R. A. Seder, and D. Sacks. 2002. Optimisation of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.
29. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138-146.
30. Oh, Y. K., J. P. Kim, T. S. Hwang, J. J. Ko, J. J. M. Kim, J. S. Yang, and C. K. Kim. 2001. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 19:4519-4525.
31. Okuno, T., M. Takeuchi, Y. Matsumoto, H. Otsuka, and Y. Matsumoto. 2002. Pretreatment of Leishmania homologue of receptors for activated C kinase (LACK) promotes disease progression caused by Leishmania amazonensis. Exp. Anim. 51:335-341.
32. Pinto, E. F., M. M. Cortezia, and B. Rossi-Bergmann. 2003. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis. Vaccine 21:3534-3541.
33. Pompeu, M. M. L., C. Brodskyn, M. J. Teixeira, J. Clarencio, J. Van Weyenberg, I. C. B. Coelho, S. A. Cardoso, A. Barral, and M. Barral-Netto. 2001. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infect. Immun. 69:7453-7460.
34. Ramiro M. J., J. J. Zarate, T. Hanke, D. Rodriguez, J. R. Rodriguez, M. Esteban, J. Lucientes, J. A. Castillo, and V. Larraga. 2003. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21:2474-2484.
35. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177.
36. Rossi-Bergmann B., A. Lenglet, C. R. Bezerra-Santos, D. Costa-Pinto, and Y. M. Traub-Czeko. 1999. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem. Inst. Oswaldo Cruz 94(Suppl. II):74.
37. Shah, J. A., P. A. Darrah, D. R. Ambrozak, T. N. Turon, S. Mendez, J. Kirman, C. Y. Wu, N. Glaichenhaus, and R. A. Seder. 2003. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J. Exp. Med. 198:281-291.
38. World Health Organization/TDR. 1999. Tropical diseases research - leishmaniasis. Fourteen Programme Report 22. World Health Organization, Geneva, Switzerland.
39. Xu, D., and F. Y. Liew. 1994. Genetic vaccination against leishmaniasis. Vaccine 12:1534-1536.